Free Trial
→ The next market Nvidia is positioned to dominate … (From Weiss Ratings) (Ad)

3 reasons 2024 Moderna shareholders may party like it's 2021

Written by MarketBeat Staff | Reviewed by Don Miller
January 5, 2024

Key Points

  • Moderna has a dominant grasp on the Covid vaccine market — and a significant revenue contributor for years to come.
  • Moderna’s second commercialized product is expected to be the RSV vaccine MRNA-1345, a catalyst Moderna shareholders have long awaited.
  • Oppenheimer analyst Hartaj Singh kicked off the new year by upgrading MRNA to a Buy.
  • MarketBeat previews the top five stocks to own by May 1st.

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Upgrade Now See Benefits

Already have an account? Log in here.

Should You Invest $1,000 in Moderna Right Now?

Before you consider Moderna, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.

While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover
These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Moderna (MRNA)
4.325 of 5 stars		$28.54+2.6%N/A-3.08Hold$58.70
Merck & Co., Inc. (MRK)
5 of 5 stars		$85.23+0.6%3.80%12.66Moderate Buy$111.13
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

7 Inflation-Proof Stocks to Protect Your Portfolio
February 5, 2025

7 Inflation-Proof Stocks to Protect Your Portfolio

Inflation is sticking around—is your portfolio ready? In this video, we break down 7 stocks that could help shield your investments from inflation’s impact.

Watch Video

Recent Videos

5 Stocks to BUY NOW in May 2025
3 Stocks Offering Rare Generational Buying Opportunities
Make Your Money Work Harder: The Power of Dividend Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines